Biocon informs about updates

19 Nov 2025 Evaluate

Biocon has informed that Biocon Pharma, a wholly owned subsidiary of the Company, has received approval from the U.S Food and Drug Administration (U.S. FDA) for its ANDA for Tofacitinib Extended Release Tablets. Final approval received for 11mg strength and tentative approval for 22mg strength. Tofacitinib extended-release tablets are a Janus kinase (JAK) inhibitor indicated for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Ulcerative Colitis. The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products.

The above information is a part of company’s filings submitted to BSE.


Biocon Share Price

391.75 3.50 (0.90%)
05-Dec-2025 14:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.45
Dr. Reddys Lab 1275.00
Cipla 1525.55
Zydus Lifesciences 933.70
Lupin 2101.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×